First Dedicated Heart and Vascular Hospital in Waxahachie Opening Soon

Baylor Scott & White Heart and Vascular Hospital – Waxahachie*, an expansion of the nationally recognized Baylor Scott & White Heart and Vascular Hospital – Dallas*, is now complete.

THT 2023 Late-Breaking Clinical Science Announced

The full list of late-breaking clinical science to be presented at THT 2023: Technology and Heart Failure Therapeutics is now available online. An international heart failure conference organized by the Cardiovascular Research Foundation (CRF), THT will take place March 20-22, 2023, at the Westin Boston Seaport in Boston, MA.

Randomized Clinical Trial Finds No Mortality Risk or Benefit Associated with Drug-Coated Devices in the Treatment of Peripheral Artery Disease

A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used.